These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39353441)

  • 1. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.
    Chang Y; Wang X; Yang J; Tien JC; Mannan R; Cruz G; Zhang Y; Vo JN; Magnuson B; Mahapatra S; Cho H; Dhanasekaran SM; Wang C; Wang Z; Zhou L; Zhou K; Zhou Y; Zhang P; Huang W; Xiao L; Liu WR; Hamadeh R; Su F; Wang R; Miner SJ; Cao X; Cheng Y; Mehra R; Ding K; Chinnaiyan AM
    Cell Rep Med; 2024 Oct; 5(10):101752. PubMed ID: 39353441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader.
    Zhou L; Zhou K; Chang Y; Yang J; Fan B; Su Y; Li Z; Mannan R; Mahapatra S; Ding M; Zhou F; Huang W; Ren X; Xu J; Wang GX; Zhang J; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 Oct; 67(20):18247-18264. PubMed ID: 39388374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
    Tien JC; Luo J; Chang Y; Zhang Y; Cheng Y; Wang X; Yang J; Mannan R; Mahapatra S; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Chou J; Lord CJ; Ding K; Chinnaiyan AM
    Cell Rep Med; 2024 Oct; 5(10):101758. PubMed ID: 39368479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
    Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma.
    Li Z; Li X; Seebacher NA; Liu X; Wu W; Yu S; Hornicek FJ; Huang C; Duan Z
    Carcinogenesis; 2024 Oct; 45(10):786-798. PubMed ID: 39082894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
    Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
    Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.
    Chan QK; Lam HM; Ng CF; Lee AY; Chan ES; Ng HK; Ho SM; Lau KM
    Cell Death Differ; 2010 Sep; 17(9):1511-23. PubMed ID: 20203690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
    Wei M; Zhao R; Cao Y; Wei Y; Li M; Dong Z; Liu Y; Ruan H; Li Y; Cao S; Tang Z; Zhou Y; Song W; Wang Y; Wang J; Yang G; Yang C
    Eur J Med Chem; 2021 Jan; 209():112903. PubMed ID: 33256948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
    Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
    Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Song J; Yu J; Jeong LS; Lee SK
    Cancer Lett; 2021 Jan; 497():54-65. PubMed ID: 33075425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway.
    Lu Z; Zhou R; Kong Y; Wang J; Xia W; Guo J; Liu J; Sun H; Liu K; Yang J; Mi M; Xu H
    Curr Cancer Drug Targets; 2016; 16(5):455-65. PubMed ID: 26638886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.
    Wu Z; Zhu Q; Yin Y; Kang D; Cao R; Tian Q; Zhang Y; Lu S; Liu P
    Cancer Med; 2018 Apr; 7(4):1546-1559. PubMed ID: 29533017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.